Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US8760334081
Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.02 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -30.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 34.2 | |||||
| 3-Year EPS without NRI Growth Rate | 36.1 | |||||
| 3-Year FCF Growth Rate | 33.1 | |||||
| 3-Year Book Growth Rate | -33.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.99 | |||||
| 9-Day RSI | 35.78 | |||||
| 14-Day RSI | 41.46 | |||||
| 6-1 Month Momentum % | 27.43 | |||||
| 12-1 Month Momentum % | 303.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.57 | |||||
| Quick Ratio | 5.57 | |||||
| Cash Ratio | 4.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.6 | |||||
| Shareholder Yield % | 3.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -437.83 | |||||
| Net Margin % | -235.34 | |||||
| FCF Margin % | -472.94 | |||||
| ROE % | -48.28 | |||||
| ROA % | -34.06 | |||||
| ROIC % | -181.06 | |||||
| ROC (Joel Greenblatt) % | -85.89 | |||||
| ROCE % | -77.26 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.33 | |||||
| PB Ratio | 2.62 | |||||
| Price-to-Tangible-Book | 2.62 | |||||
| EV-to-EBIT | -1.21 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Revenue | 5.28 | |||||
| EV-to-Forward-Revenue | 0.56 | |||||
| EV-to-FCF | -1.11 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Price-to-Net-Cash | 3.07 | |||||
| Earnings Yield (Greenblatt) % | -82.64 | |||||
| FCF Yield % | -44.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRKR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Marker Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.5 | ||
| EPS (TTM) ($) | -0.94 | ||
| Beta | 1.62 | ||
| Volatility % | 175.48 | ||
| 14-Day RSI | 41.46 | ||
| 14-Day ATR ($) | 0.320762 | ||
| 20-Day SMA ($) | 4.52426 | ||
| 12-1 Month Momentum % | 303.74 | ||
| 52-Week Range ($) | 0.76 - 9.6799 | ||
| Shares Outstanding (Mil) | 8.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marker Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(MRKR)'s stock price today?
The current price of MRKR is $4.14. The 52 week high of MRKR is $9.68 and 52 week low is $0.76.
When is next earnings date of Marker Therapeutics Inc(MRKR)?
The next earnings date of Marker Therapeutics Inc(MRKR) is 2024-05-15 Est..
Does Marker Therapeutics Inc(MRKR) pay dividends? If so, how much?
Marker Therapeutics Inc(MRKR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers